Prescription Patterns of Novel Antihyperglycemic Medications
Recommended Citation
Ali AS, Khan M, Ortega D, Jaffery S, Lamerato LE, and Budzynska K. Prescription Patterns of Novel Antihyperglycemic Medications. J Am Board Fam Med 2022; 35(2):255-264.
Document Type
Article
Publication Date
1-1-2022
Publication Title
J Am Board Fam Med
Abstract
BACKGROUND: Glucagon-like peptide-1 agonists (GLP-1a) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are recommended in carefully selected patients with type 2 diabetes. This study will assess prescription of these medications and investigate predictors of prescription.
METHODS: This retrospective cross-sectional study included 31,354 patients. Data including sociodemographic descriptors, clinical histories, medications, and health insurance providers were extracted from a health system's administrative databases. Variables to be associated with prescription of a GLP-1a or SGLT-2i were assessed using a multivariable logistic regression model.
RESULTS: Mean age was 62.58 years and 40.8% identified as African American. Only 3.4% were prescribed a GLP-1a and 2.1% received a SGLT-2i. Logistic regression demonstrated lower odds of receiving either medication in the highest age-group (70 to 79 years) (GLP-1a: odds ratio [OR] 0.44,
CONCLUSIONS: Prescription of GLP-1a and SGLT-2i medications was low as compared with existing literature. Advanced age and African American race were negatively associated with prescription of these medications. Contrary to guideline recommendations; atherosclerotic cardiovascular disease and chronic kidney disease were not positively associated with prescription.
Medical Subject Headings
Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Middle Aged; Prescriptions; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors
PubMed ID
35379713
Volume
35
Issue
2
First Page
255
Last Page
264
